Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of Cloretazine® (VNP40101M) and Temodar® (Temozolomide) for Patients With Malignant Glioma in First Relapse or Progression

NCT00516282 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT00516282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00516282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of Cloretazine® (VNP40101M) and Temodar® (Temozolomide) for Patients With Malignant Glioma in First Relapse or Progression
Lead sponsor
Northwestern University
Phase
Phase 1
Overall status
Terminated
Start date
August 31, 2007
Completion date
October 31, 2009
Enrollment
14 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors